Electronic Supplementary Material (ESI) for Nanoscale. This journal is © The Royal Society of Chemistry 2021

## **Supplementary information**

#### **Biomimetic Microcavity Interface for Label-free Capture of Pathogens in Fluid**

#### **Bloodstream by Vortical Crossflow Filtration**

Liyuan Zheng,<sup>†1,2,3</sup> Xiaobo Zheng,<sup>†4</sup> Shanshan Yuan,<sup>1,2,8</sup> Weide Xu,<sup>1,2</sup> Changhuan Zhang,<sup>1,2</sup>

Xingding Zhang,<sup>3</sup> Zhiyuan Fan,<sup>5</sup> Jilong Wang,<sup>1,2,8</sup> Zheng Wang,<sup>\*6</sup> Jinhai Huang<sup>\*4,7</sup> and Junjie Deng,<sup>\*1,2,8</sup>

<sup>1</sup>Joint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China. E-mail: j.deng@wiucas.ac.cn

<sup>2</sup> Joint Centre of Translational Medicine, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, China.

<sup>3.</sup> School of Medicine (Shenzhen), Sun Yat-sen University, Guangzhou 510080, China.

<sup>4</sup> School of Biomedical Engineering, School of Ophthalmology and Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou 325011, China.

<sup>5</sup> Department of Materials Science and Engineering Drexel University, Philadelphia, PA 19104, USA.

<sup>6</sup> Research Center of Blood Transfusion Medicine, Ministry of Education Key Laboratory of Laboratory Medicine, Department of Blood Transfusion, Zhejiang Provincial People's Hospital of Hangzhou Medical College Hangzhou 310014, China.

<sup>7</sup>Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University; Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China.

<sup>8</sup> Oujiang Laboratory, (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, Zhejiang 325000, China.

\**E-mail:* <u>j.deng@ucas.ac.cn</u> (J. J. Deng); <u>wangzhen@hmc.edu.cn</u> (Z. Wang) and <u>vip999vip@163.com</u> (J. H. Huang)

## **Experimental Section**

Materials. Single-crystal silicon wafers (N-type phosphorus-doped, (100)-orientation, resistivity 1-10  $\Omega$  cm, 100 mm diameter, thickness 625 µm) were purchased from KAYEX (Rochester, MN, USA). Lotion, acetone (98%), ethanol (99.8%), nitric acid (69 wt.%), hydrofluoric acid (48 wt.%), glycerol, sodium chloride, sodium carbonate and sodium carboxymethyl cellulose (600 mpa.s) were purchased from Mecox Lane (Shanghai, China) without further purification. The photoresist S1813 was purchased from Micro Chem Corp (Santa Clara, CA, USA). Silver nitrate (AgNO3), isopropyl-β-D-thiogalactopyranoside (IPTG), NHS-rhodamine B and ampicillin (AMP) were purchased from Sigma-Aldrich. Glutaraldehyde (25 wt.%) and heparin were purchased from Alfa-Aesar. The yeast extract and tryptone of Luria-Bertani medium (LB) were obtained from Beijing Shuangxuan Microbe Culture Medium Products Factory (Beijing, China). Phosphate buffered saline (PBS), the LIVE/DEAD BacLight Bacterial Viability kit, Calcein Acetoxymethyl seter (AM)/propidium Iodide (PI) Viability Dye kit and human C5a&C4d ELISA kit were purchased from Thermo Fisher Scientific. The Rhodamine phalloidin was purchased from Invitrogen. The Human PF4 ELISA kit were obtained from Abcam. The Staphylococcus aureus bacteria strain was purchased from Invitrogen (Karlsruhe, Germany). The biovector of PET 6XH7S/EFGP and BL21 E. coli strain were purchased from NTCC (Beijing, China). Deionized (DI) water was obtained from Merck Millipore water purification system and used for all experiments. All reagents were used as received. Blood was obtained from anonymized healthy volunteers from Wenzhou Medical University and used under protocols approved by the Ethics Committee at Wenzhou Medical University (serial number: 2021-22-055).

#### Methods

**Bacteria Culture and Staining.** Plasmid DNA of PET 6XH7S/eGFP was transferred into Escherichia coli BL21 (DE3) competent cells, and then positive colons were selected by cultivation on LB plates with 100  $\mu$ g mL<sup>-1</sup> ampicillin. Z Subsequently, the single eGFP-

expressing *E. coli* colony was cultured in 20 mL of LB media containing 1 mM L-1 IPTG and 100 µg mL<sup>-1</sup> AMP. After 12 h growing at 26 °C while being agitated at 100 rpm min-1 in an orbital shaker incubator, bacteria were harvested by centrifugation at 1200 × g for 5 min, and then the pellet was resuspended in PBS buffer for further experiments. To prepare *S. aureus* suspension, 100 µL of *S. aureus* stock solution was defrosted and inculcated into 25 mL of LB media overnight at 37 °C with shaking at 110 rpm min<sup>-1</sup>. Afterwards, 100 µL of bacteria suspension was transferred into another tube containing 50 mL of LB media for further culture in the shaking incubator until cell densities (OD600) reached 0.6~0.8, which corresponded to the concentration of ~10<sup>6</sup>-10<sup>8</sup> CFU mL<sup>-1</sup>. Subsequently, the bacteria were collected by centrifugation at 1200 × g for 5 min, and followed by gently washing in PBS solution for 2 times. Next, the bacteria were stained in PBS containing 0.15% (vol/vol) component B of LIVE/DEAD BacLight Bacterial Viability kit for 10 min under dark condition. Finally, bacteria were harvested for further use.

**Bacteria Morphology.** The microcavity interfaces (SNMA<sub>30/10</sub>, SNMA<sub>30/7</sub>, SNMA<sub>50/10</sub>, SNMA<sub>50/7</sub> and PSN) which treated with cross-flowing filtration were fixed with 2.5% (V/V) glutaraldehyde solution in 0.01 M PBS and stored at 4 °C. After 12 h, microcavity interfaces were washed with PBS and dehydrated through ethanol with concentration gradients (25%, 50%, 75%, 90%, 95% and 100%) for 15 min with each step and last step twice. Then the samples were lyophilized overnight. For high contrast imaging, all samples were sputter-coated with platinum in a sputtering device (Leica EM ACE200) and observed using SEM.

**Statistical Analysis.** All data were presented as means  $\pm$  s.d. from three or more than three replicates. Two group comparisons were made using two-tailed Student's T-tests. Statistical significances were analyzed by using the SPSS (Statistical Product and Service Solutions Software, version 22.0). *P values* < 0.05 were considered statistically significant with \**P* < 0.05 and \*\**P* < 0.01. *P values* > 0.05 were considered non-significant (ns).

# **Supporting Figures**



Scheme S1 Schematic diagram of microstructure of photomask. Diameter = 7  $\mu$ m or 10  $\mu$ m and center distance = 30  $\mu$ m or 50  $\mu$ m.



Figure S1 The microscopy images of SPMA<sub>30/10</sub>, SNMA<sub>30/10</sub>, SNMA<sub>50/10</sub>, SNMA<sub>30/7</sub> and

 $SNMA_{50/7},$  scale bar: 100  $\mu m.$ 



Figure S2 The 3D AFM image of SNMA<sub>50/10</sub>.



**Figure S3** The average microcavity depth of SPMA<sub>30/10</sub> (A), SPMA<sub>30/7</sub> (B), SPMA<sub>50/10</sub> (C), SPMA<sub>50/7</sub> (D), SNMA<sub>30/7</sub> (E), SNMA<sub>30/10</sub> (F), SNMA<sub>50/7</sub> (G) and SNMA<sub>50/10</sub> (H) by stylus profiler measurement. Data were presented as means  $\pm$  s.d. (n=5 per group).



**Figure S4** Morphologies of water droplets on the surfaces of monocrystalline silicon, PSN, SPMA and SNMA without plasma treatment or with plasma treatment. The Eigen contact angles were analyzed using contact angle meter. Data were presented as means  $\pm$  s.d. (n=3 per group).



**Figure S5** The real-time fluorescence images of SNMA<sub>30/10</sub> under cross-flowing treatment of *E*. *coli* solution at a concentration of  $6 \times 10^6$  CFU mL<sup>-1</sup>. Scale bar: 50 µm.



Figure S6 SEM images of plasma-treated PSN, SNMA<sub>50/10</sub> and SNMA<sub>50/7</sub> after cross-flowing

treatment of *E. coli* solution. Scale bar: 2 µm.



**Figure S7** Representative fluorescence images of suspended bacteria treated with cross-flowing treatment with eGFP-expressing *E. coli* following with static culture treatment.



**Figure S8** Representative fluorescence images of PSN, SPMA<sub>30/10</sub> and SNMA<sub>30/7</sub> after crossflowing treatment of *E. coli* in the LB and artificial blood medium. The concentration of *E. coli* was  $6 \times 10^6$  CFU mL<sup>-1</sup>, the flow velocity was 8.5 cm s<sup>-1</sup> and the flow entering angle was 30°. The Scale bar: 50 µm.



**Figure S9** (A) Representative fluorescence images of *E. coli* in human blood before or after cross-flowing treatment from PSN. Scale bar: 50 µm. A representative photograph of agar plates with colonies growing from *E. coli* in the original bacteria suspension or the bacteria suspension after cross-flowing treatment from PSN. (B) Representative fluorescence images of *E. coli* in human blood before or after cross-flowing treatment from SNMA<sub>30/10</sub>. Scale bar: 50 µm. A representative photograph of agar plates with colonies growing from *E. coli* in the original bacteria suspension or the bacteria suspension or the bacteria suspension of the bacteria suspension or the bacteria suspension of agar plates with colonies growing from *E. coli* in the original bacteria suspension or the bacteria suspension after cross-flowing treatment from SNMA<sub>30/10</sub>. Scale bar: 50 µm. A representative photograph of agar plates with colonies growing from *E. coli* in the original bacteria suspension or the bacteria suspension after cross-flowing treatment from SNMA<sub>30/10</sub>. (C) The bacterial capture efficiency of PSN and SNMA<sub>30/10</sub> after human blood cross-flowing treatment. The concentration of *E. coli* in human blood was  $6 \times 10^6$  CFU mL<sup>-1</sup>. The flowing velocity was 8.5 cm s<sup>-1</sup> and the flowing entering angle was 30°. Data were presented as means ± s.d. (n=10 per group).



**Figure S10** Representative fluorescence images of (A) SNMA<sub>30/10</sub> and (B) SNMA<sub>30/7</sub> cultured with *s. aureus* solution at a concentration of  $0.6 \times 10^6$  CFU mL<sup>-1</sup> under static culture and cross-flowing treatment, respectively. Scale bar: 30 µm. Photos of agar plates with colonies growing from the residual *s. aureus* in human blood after cross-flowing treatment from SNMA<sub>30/10</sub> and SNMA<sub>30/7</sub>. (C) The bacterial capture efficiency of SNMA<sub>30/10</sub> and SNMA<sub>30/7</sub> after human blood cross-flowing treatment. The concentration of *s. aureus* in human blood was  $0.6 \times 10^6$  CFU mL<sup>-1</sup>. The flowing velocity was 8.5 cm s<sup>-1</sup> and the flowing entering angle was 30°. (D) Fluorescence intensities of *s. aureus* inside microcavities of SNMA<sub>30/10</sub> and SNMA<sub>30/7</sub> after different treatments. Fluorescence intensities were measured by microscopy using Image J software. Data were presented as means ± s.d. (n=10 per group). ns = no significance, \*\*p < 0.01.



**Figure S11** Fluid blood cleaning using biomimetic microcavity interface. Representative fluorescence images of newly synthesized SNMA<sub>30/7</sub> (A) and recycled materials SNMA<sub>30/7</sub> (B) after cross-flowing treatment of human blood containing E.coli at  $6 \times 10^{6}$  CFU mL<sup>-1</sup>. (C) The capture efficiencies of newly synthesized SNMA<sub>30/7</sub> and recycled materials SNMA<sub>30/7</sub> after cross-flowing treatment of *E. coli* in human blood.



**Figure S12** The fluorescence images of blood cells trapped in  $SNMA_{30/7}$  and  $SNMA_{30/10}$  after human blood cross-flowing treatment. Green fluorescence indicated live cells; red fluorescence indicated dead cells. Scale bar: 100 µm.



**Figure S13** (A) A representative fluorescence image of SNMA<sub>30/10</sub> when 50  $\mu$ L of blood containing fluorescent BSA was deposited onto the microcavity interface before cross-flowing treatment. (B) A representative fluorescence image of SNMA<sub>30/10</sub> after cross-flowing treatment of blood containing fluorescent BSA. The flow velocity was 8.5 cm s<sup>-1</sup> and the flow entering angle was 30°. BSA was labeled with rhodamine-B in PBS solution at a concentration of 2 mg mL<sup>-1</sup>. Scale bar: 100  $\mu$ m.



**Figure S14** The simulated total resistance of fluid in microcavities with an opening diameter of 10  $\mu$ m or 7  $\mu$ m in SPMA, SNMA-LSN and SNMA-HSN. The slopes of nanowires in SNMA-LSN and SNMA-HSN were 0.48 and 5.33, respectively, which were calculated as the nanowire height divided by half of the bottom width. The flow entering velocity was simulated as 8.5 cm.s<sup>-1</sup>.



**Figure S15** The simulated flow velocity of the solution in microcavities with a diameter of 10  $\mu$ m (A) or 7  $\mu$ m (B) as a function of the microcavity height. The points were collected from the geometric center of the bottom circle to the geometric center of the top circle. SNMA-LSN meant SNMA with low-slope nanowires. SNMA-HSN meant SNMA with high-slope nanowires. The flow entering velocity was 8.5 cm s<sup>-1</sup> and the flow entering angle was 30°.

Sample	Microcavity depth (nm)*	Microcavity depth (nm)**
SPN	115±25	-
SPMA <sub>30/10</sub>	1731±19	-
SPMA <sub>30/7</sub>	1703±22	-
SPMA <sub>50/10</sub>	1730±62	-
SPMA <sub>50/7</sub>	1701±16	-
SNMA <sub>50/10</sub>	800±55	1046±104
SNMA <sub>50/7</sub>	944±78	1134±101
SNMA <sub>30/10</sub>	176±10	246±57
SNMA <sub>30/7</sub>	389±19	439±65

# Table S1 Microcavity depth of microcavity interface

\* Microcavity depth was detected using stylus profiler;

\*\* Microcavity depth was detected using atomic force microscopy (AFM);